Conference Coverage

Obesity may attenuate anti-TNF response in psoriatic arthritis


 

References

DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.

Pages

Recommended Reading

After Inflectra’s approval, challenges remain for biosimilars
MDedge Rheumatology
Effective psoriasis therapy may reduce coronary plaque burden
MDedge Rheumatology
Remicade to infliximab biosimilar switches fare well in real-life practice
MDedge Rheumatology
Brodalumab effective for rare, severe types of psoriasis
MDedge Rheumatology
PIANO study provides insight on safety of biologics in pregnancy
MDedge Rheumatology
Serious infections are increasing among psoriasis inpatients
MDedge Rheumatology
Doctors ask Congress to stop Part B drug payment test
MDedge Rheumatology
Full resolution of psoriasis in half of ixekizumab patients
MDedge Rheumatology
TNF blocker safety may differ in RA and psoriasis patients
MDedge Rheumatology
TB still a risk in psoriasis patients taking TNF blockers
MDedge Rheumatology